Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$8.96M$8.96M+21.2% vs Q3 2023 Net Income$947.92M$947.92MN/M vs Q3 2023 EPS Diluted$16.22$16.22N/M vs Q3 2023 Operating Income-$102,811,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$84,637,000N/M Margins · derivedOperating margin-1146.9%+216.7 pt vs Q3 2023
Net margin10574.7%+11809.0 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 31, 2024 · 31 d after period end